|
1000
|
Abstract/Summary
|
-
<jats:title>Summary</jats:title><jats:p>Allogeneic stem cell transplantation (alloSCT) is the only curative treatment option for patients with high-risk myelofibrosis (MF). However, it is important to bear in mind that alloSCT in MF is associated with a nonrelapse mortality that should not be underestimated. Therefore, both exact disease risk categorization and thorough evaluation of the individual transplant-related risk are mandatory to identify those patients to whom alloSCT should be offered. This short review is intended to provide a concise overview on relevant aspects to be considered for patient selection, planning, and performing alloSCT.</jats:p>
|
|
1000
|
Hinweis
|
-
DeepGreen-ID: d6e63deac43f423b9c0fb0b9e3d31a40 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
|
